Transglutaminases (TGs) are members of a family of enzymes that catalyze the incorporation of primary amino groups in various compounds into proteins, or catalyze the cross-linking of protein assemblies, in a calcium-dependent manner. There are eight enzymatically active members of the mammalian TG family, designated TG1 to TG7 and factor XIIIA (fXIIIA). The diversity of their catalytic actions extends to many critical biological functions. These include covalent stabilization of protein assemblies-a reaction central, for example, to hemostasis through fibrin polymer formation during blood clotting; linkage of lipids to protein scaffolds, an action underlying the integrity of the skin's barrier function that is critical for preventing transdermal infection and dehydration; and even deamidation of key glutamine residues-a reaction that is likely to be directly involved in the pathogenesis of major clinical disorders, such as gluten-induced enteropathy or celiac disease (1) .
TG2 as a G Protein for GPCRs
The involvement of TGs in receptor signaling-in particular, in signaling by the superfamily of G protein-coupled receptors (GPCRs) (Fig. 1 )-has been quite unexpected and is a relatively recent discovery. GPCRs constitute one of the largest and most diverse families of proteins in mammals and are of immense therapeutic relevance, with 40 to 50% of all currently available drugs targeting these receptors (2) . The intriguing report from Richard Hynes' laboratory (3) that a TG may be the ligand for an orphan GPCR, GPR56, which regulates growth and metastatic potential of melanoma cells, is the most recent chapter in this evolving saga. The first report linking TGs and receptor function-specifically, receptor-mediated endocytosis-was published in 1980 (4) and was received with much interest at the time. However, this action was not supported by subsequent studies (5) . In 1987, Achyuthan and Greenberg (6) reported that, unlike other members of the then-known TG family, TG2 binds and hydrolyzes guanosine triphosphate (GTP). Nonetheless, a link between TGs and GPCR signaling was not established until the serendipitous discovery that a GTP-binding protein, termed G h on the basis of its atypical, high molecular weight (~74 kD, versus 40 to 45 kD for the GTP-binding α subunits of heterotrimeric G proteins), which copurified with the α 1B -adrenergic receptor, a class A GPCR, was in fact identical to TG2 (7) . Subsequently, analogous to the heterotrimeric G proteins Gα q and Gα 11 , TG2 was shown to mediate signaling by several GPCRs that activate phospholipase C, including also the α 1D -adrenergic receptor, thromboxane A2, and oxytocin receptors (1). This action is independent of its cross-linking activity (8) ; in fact, binding of GTP allosterically inhibits the catalytic activity of TG2 and of other GTP-binding TGs such as TG3 and TG5. Under the extant concentrations of calcium and GTP present in a healthy cell, the catalytic activity of TG2 is largely latent and TG2 functions as a receptor-coupled G protein. In cell disruption-due, for example, to apoptosis, when loss of membrane integrity allows the intracellular calcium concentration to rise and synthesis of GTP is impaired-the catalytic activity of TG2 is stimulated and it cross-links intracellular proteins, thereby preventing both their loss into the extracellular environment and the activation of an inflammatory response (9, 10) .
GPCR Dimerization by a TG
An equally serendipitous discovery was made by AbdAlla and colleagues (11), who followed a lead by others that monocytes from hypertensive patients are activated and show enhanced adhesion to endothelial cells (12) . They noted that although monocytes isolated from normotensive subjects and patients with hypertension expressed similar amounts of the type 1 angiotensin II (AT 1 ) receptor, the receptor was monomeric in the normotensive subjects but appeared to form a covalently linked dimer that was resistant to reduction and denaturation in hypertensive patients. Typically, fXIII is an extracellular enzyme that circulates in blood in association with its regulatory B subunit as an A 2 B 2 heterotetramer and requires proteolytic cleavage by thrombin as well as calcium for activation (1) . However, monocytes express the catalytic A subunit of fXIII in the absence of its regulatory B subunit and fXIIIA can be activated by calcium alone (13) . With these considerations in mind, AbdAlla et al. (11) investigated fXIIIA levels and found enhanced expression and activity in hypertensive monocytes, and further identified a glutamine residue (Gln 315 ) in the tail of the AT 1 receptor as the target of fXIIIA-mediated cross-linking. Additionally, they showed that treatment of normal cells with angiotensin II and the calcium ionophore ionomycin induced AT 1 receptor dimerization, whereas mutagenic substitution of Gln 315 with alanine-a residue that cannot support fXIIIA-mediated crosslinking-prevented both AT 1 dimerization and enhanced AT 1 signaling, an effect also observed in cells obtained from fXIIIA-deficient patients that expressed the native AT 1 receptor. Finally, in studies of mice with hypercholesterolemia due to inactivation of the apolipoprotein E gene-a model of angiotensin II-dependent atherosclerosis-inhibition of angiotensinconverting enzyme (ACE) or suppression of fXIIIA expression reduced monocyte infiltration and vascular lesions in the aorta. These results are of interest for several reasons: (i) Blood pressure is regulated in part by the renin-angiotensin system, which generates the AT 1 receptor-activating peptide hormone angiotensin II through an enzyme cascade involving ACE. Furthermore, overactivity of this system results in hypertension and renal and cardiac dysfunction (14) . that may display an altered pharmacology and responsiveness (14) . (iii) Monocytes from hypertensive patients not only released more cytokines in response to angiotensin II stimulation, but also formed more of the peptide hormone as a result of their ACE activity being stimulated (11) .
In addition to providing one of the first mechanistic links to explain the accelerated atherosclerosis observed in patients with hypertension, this study provides evidence for an entirely novel mechanism for regulating GPCR signaling through covalent fXIIIA-mediated dimerization-an effect that amplifies the receptor signal by enhancing downstream effector activation. The mechanism underlying this altered signaling remains to be determined. Nor is it yet known how enhanced AT 1 signaling promotes increased monocyte adhesion and whether cross-linking of the AT 1 receptor monomers involves linkage by means of a diamino compound, or coupling of Gln 315 to an as-yet-unidentified AT 1 receptor lysyl residue.
TG2 as a Ligand for a GPCR
In addition to TGs functioning intracellularly as G proteins for GPCRs or modulating receptor signaling by promoting GPCR dimerization, Xu et al. (3) reported that TG2 can function extracellularly as the ligand for the orphan GPCR GPR56. This receptor was originally cloned (15) as a result of efforts to identify additional members of the class B or secretin-like family of GPCRs (which also includes receptors for calcitonin, parathyroid hormone, vasoactive intestinal peptide, glucagon, glucagonlike peptide 1, growth hormone releasing factor, pituitary adenylate cyclase-activating polypeptide, and corticotropin-releasing factor) and was simultaneously discovered by differential display in a screen of melanoma cells for genes whose expression correlates with differing metastatic potential (16) . This latter study demonstrated that its expression is inversely proportional to the potential for melanoma cells to metastasize.
Although showing sequence similarity with other class B GPCRs, GPR56 differs from the secretin-like family by the presence of both a long N terminus and a juxtamembranous, cysteine-rich GPS (GPCR proteolytic site) motif, a cleavage site located immediately upstream of its first transmembrane (TM) segment. This and other structural features, including multiple potential sites for O-and N-linked glycosylation in the N-terminal segment, as observed in mucin-like proteins, identify GPR56 as a member of the LNB (long N terminus, class B) subfamily of GPCRs [now known as the adhesion GPCR subfamily (2)]. These receptors are cotranslationally processed by cleavage at the GPS motif, with the resulting N-terminal fragment (NTF), although not containing a TM domain, remaining linked to its C-terminal fragment (CTF), albeit noncovalently and not through a disulfide linkage (17) . Although much remains to be learned about this GPCR subfamily, studies of latrophilin-one subfamily member for which the ligand has been identified-indicate that activation involves binding of the ligand to the NTF (17) . This then results in the productive association with the CTF required for effector activation. Also of interest is the finding that GPR56 associates in the plasma membrane with the tetraspanins CD9 and CD81-membranespanning scaffold proteins that link receptors with intracellular signaling molecules-and that this complex facilitates associa- tion of GPR56 with G proteins of the Gα q /Gα 11 family and their β subunit, Gβ (18) .
P E R S P E C T I V E

Gβ
Having confirmed the findings of Zendman et al. (16) , but by a microarray approach applied to melanoma cells of differing metastatic potential, Xu et al. (3) , to their credit, then explored the functional importance of altered GPR56 abundance. This revealed that whereas forced overexpression of the GPR56 suppressed both tumor growth and metastasis, suppressed expression of the receptor enhanced tumor progression. Because these effects appeared to involve an influence of the in vivo cell micorenvironment, they further sought the ligand interacting with GPR56 within the extracellular matrix. Using the NTF of GPR56 as bait, they identified and then confirmed that TG2 interacts specifically, through its two C-terminal β-barrel domains, with the receptor.
Taken together, these findings indicate that GPR56 inhibits tumor growth and metastatic spread through a mechanism involving interaction with TG2. Nonetheless, it may be premature to designate TG2 as a ligand for GPR56, given that activation of the receptor by either holoTG2 or its C-terminal β barrels was not demonstrated. Moreover, given the association of GPR56 with tetraspanins, TG2 may merely function as a scaffold protein or, as demonstrated for integrins, as a coreceptor for matrix proteins. In the case of integrins, this involves stabilization of the interaction between β1-or β3-integrins and their matrix ligand, fibronectin (19) . Whether the catalytic cross-linking activity or GTP-binding ability of TG2 is required for its interaction with GPR56 also remains unclear; the high-calcium, low-GTP environment of the extracellular milieu favors the former but not the latter, although in the case of TG2's role as an integrin-binding coreceptor for fibronectin, probably neither is required.
Assuming that TG2 is indeed a ligand for GPR56, what regulates its interaction with GPR56? Or does it constitutively activate the receptor? The intracellular signaling pathway used by GPR56 in suppressing growth and metastatic spread is clearly of great interest as well. Despite these unresolved issues, the findings of Xu et al. (3) are potentially of great relevance to the treatment of melanoma-a malignancy that carries a very poor prognosis because of its aggressive nature, promiscuous metastatic spread, and resistance to therapy-as they define for the first time what appears to be part of a major regulatory network for limiting tumor growth and metastases. It should be noted, however, that in certain tumors such as glioblastomas, expression of GPR56 is enhanced (20)-although there too it may be trying to limit tumor growth, albeit unsuccessfully. If this notion is confirmed, altered GPR56 expression may be a primary mechanism for dysregulated growth in melanoma cells but a potentially compensatory one in other tumors.
